Figure S1. SKI-I inhibits vertical growth phase melanoma cells viability. 5 × 103 WM278.1 cells containing high SPHK1 activity were exposed to increasing concentrations of SKI-I for 24, 48, and 72 h and cell viability measured using MTS.

Figure S2. SKI-I but not SKI-II reduces cellular S-1-P and induced pro-apoptotic ceramide content in 1205 Lu melanoma cells.

Figure S3. Intraperitoneal administration of SKI-I but not SKI-II retarded melanoma tumor growth.

Figure S4. SKI-I elevates caspase-3/7 activity in melanoma cells. A375M, UACC 903, and 1205 Lu cells were treated with 1, 2.5, and 5.0 μM SKI-I for 72 h and cell lysates analyzed for caspase-3/7 activity using Apo-ONE homogenous caspase-3/7 activity assay kit.

PCMR_970_sm_fs1.jpg97KSupporting info item
PCMR_970_sm_fs2.jpg115KSupporting info item
PCMR_970_sm_fs3.jpg143KSupporting info item
PCMR_970_sm_fs4.jpg108KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.